Understanding IgA Nephropathy Progression: Stages, Monitoring, and Management

IgA nephropathy (IgAN, Berger's disease) progression varies widely—some maintain stable kidney function for decades, others progress to end-stage renal disease (ESRD) within years. Understanding the trajectory helps patients and clinicians optimize monitoring and intervention.

Stages of IgA Nephropathy Progression

Early Stage

Often asymptomatic. Detected incidentally via routine urinalysis (microscopic hematuria ± proteinuria) or bloodwork (elevated creatinine). Kidney biopsy confirms IgA deposits in glomeruli.

Proteinuria

Persistent protein leakage (>0.5–1 g/day) signals active glomerular injury and is the strongest predictor of progression. Nephrotic-range proteinuria (>3.5 g/day) indicates advanced damage.

Hematuria

Blood in urine—microscopic (detected only on dipstick/microscopy) or gross (visible, often triggered by infections). Gross hematuria episodes may recur but don't always correlate with progression speed.

Decreased Kidney Function

Gradual decline in eGFR (estimated glomerular filtration rate). Stages by eGFR: G1 (≥90), G2 (60–89), G3a (45–59), G3b (30–44), G4 (15–29), G5 (<15 or dialysis).

Hypertension

Common complication and progression accelerator. Blood pressure control is a cornerstone of management.

Edema

Swelling (ankles, periorbital) from fluid retention as kidney function declines and/or nephrotic syndrome develops.

Anemia

Reduced erythropoietin production by failing kidneys → decreased red blood cell production.

End-Stage Renal Disease (ESRD)

Kidney failure requiring dialysis or transplantation. ~20–40% of IgAN patients reach ESRD within 20–25 years.

Prognostic Factors

  • Proteinuria level and duration (most critical)
  • eGFR at diagnosis
  • Histologic classification (Oxford MEST-C score)
  • Blood pressure control
  • Comorbidities (diabetes, obesity)
  • Treatment adherence

Monitoring and Management

Regular surveillance is essential: kidney function (eGFR, creatinine), urine protein-to-creatinine ratio, blood pressure, urine analysis. Early intervention—RAAS inhibition (ACEi/ARB), SGLT2 inhibitors, blood pressure optimization, lipid management, lifestyle modification—can slow or halt progression. Emerging therapies (targeted release budesonide, complement inhibitors) show promise.

Kidney Disease - Related Articles